Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Seattle, May 6 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility. “We are very pleased that Oculis has chosen us to manufacture [...]